Non-human primate-derived lactobacillus reuteri and application thereof

Through the Lactobacillus reuteri MacFasB02 strain isolated from nonhuman primates, the problem of insufficient adaptability of Lactobacillus reuteri in nonhuman primate applications in the prior art was solved, and blood lipid reduction and inhibition were achieved. The effects of weight gain, liver protection and relieve inflammation of rheumatoid arthritis have broad application prospects.

CN119020230AActive Publication Date: 2024-11-26INST OF ZOOLOGY GUANGDONG ACAD OF SCI +1
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202411412756.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-11-26
Estimated Expiration
2044-10-11

AI Technical Summary

Technical Problem

The existing Lactobacillus reuteri strains are mainly derived from humans or the same species, and are difficult to adapt to the intestinal environment of non-human primates, resulting in inconsistent effects in non-human primate applications and lack of them from non-human Primate strain research.

Method used

A strain of Lactobacillus reuteri MacFasB02 was isolated from nonhuman primates. This strain has the effects of reducing cholesterol and triglyceride levels, inhibiting weight gain, protecting the liver and alleviating inflammation of rheumatoid arthritis. Can be colonized in high fat environments and is suitable as the main ingredient in probiotic preparations.

Benefits of technology

Lactobacillus reuteri MacFasB02 strain significantly reduces blood lipid levels, inhibits weight gain, has good liver protection effects, and can relieve rheumatoid arthritis inflammation. It is suitable for lowering blood lipids, controlling weight, protecting the liver and improving motor dysfunction. The field has important application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020230A_ABST
    Figure CN119020230A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus reuteri derived from non-human primates and application thereof. According to the invention, a novel lactobacillus reuteri MacFasB02 strain is separated from excrement of cynomolgus monkeys tolerant to high fat diet, and the strain can be used for remarkably reducing LDL-C (Low-Density Lipoprotein-C) and TG (Triglyceride) levels caused by the high fat diet and can be used for reducing the blood fat level of a host; a good liver protection effect is achieved; the weight gain caused by high-fat diet can be effectively inhibited; the rheumatoid arthritis inflammation can be effectively relieved. Meanwhile, the strain also has extremely strong acid resistance and cholate resistance, is suitable for colonization in gastrointestinal tracts of primates, has natural advantages in improvement of human health, and has important application values in multiple fields of blood fat reduction, weight gain inhibition, liver protection, rheumatoid arthritis treatment and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and their application, and particularly relates to Lactobacillus reuteri derived from non-human primates and their application. Background Art

[0002] Probiotics are increasingly attracting the attention of researchers and the industry for their green and healthy advantages. Probiotics beneficially affect the health of host animals by improving the intestinal microecological balance of host animals. Many beneficial probiotic strains have been successfully developed and verified and are widely used in health foods, pharmaceuticals and dairy industries. Among them, Lactobacillus reuteri is widely present in nature and can be isolated from the intestines of vertebrates and mammals. Lactobacillus reuteri has a strong adhesion ability to the intestinal mucosa, which can improve the distribution of intestinal flora, antagonize the colonization of harmful bacteria, and avoid intestinal diseases; Lactobacillus reuteri can produce a non-protein broad-spectrum antibacterial substance called "Reuterin", which can widely inhibit the growth of Gram-positive bacteria, Gram-negative bacteria, yeast, fungi and pathogens. Lactobacillus reuteri is a Campylobacter with a slightly irregular shape and rounded ends. Lactobacillus reuteri is an obligate heterofermentation strain that can ferment sugar to produce CO2, lactic acid, acetic acid and ethanol.

[0003] Studies have shown that different strains of Lactobacillus reuteri have different physiological effects. For example, Limosilactobacillus reuteri DSMZ 17648 can be used to treat Helicobacter pylori (H.pylori), and Limosilactobacillus reuteri NCIMB 30242 can be used to treat high cholesterol. At the same time, strains from different host sources have different functional effects. Lactobacillus reuteri has multiple effects, but the application effects in actual animal production are not consistent. Due to the different intestinal environments of different animals, probiotics from different host sources have different adaptability to the intestinal tract of animals, which affects their colonization and function. Probiotics derived from the intestines of the same animal can overcome adverse factors in the digestive tract and the adverse effects of other microbial communities, colonize quickly, and thus quickly play a role. Therefore, the advantages of homologous probiotics have been highly valued.

[0004] Non-human primates have great homology with humans in terms of genetic genes, with a gene sequence homology of up to 93-97.5%, and their intestinal morphology, metabolic mechanism and physiological functions are highly similar to those of humans. However, there are no reports of successful isolation of Lactobacillus reuteri from non-human primates. Therefore, exploring Lactobacillus reuteri from non-human primates to treat diseases and improve human health is conducive to enhancing the actual application effect and filling the gaps in the corresponding fields. At the same time, it plays a very important role in enriching the existing market sources of probiotics and improving the quality and efficacy of existing market probiotic products. Summary of the invention

[0005] In order to overcome the deficiencies of the above-mentioned prior art, the present invention isolates a Lactobacillus reuteri (Limosilactobacillus reuteri) MacFasB02 strain from primates, which can reduce the level of low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), inhibit weight gain, protect the liver, and has the effects of relieving rheumatoid arthritis inflammation and improving motor dysfunction, and has important potential application value in the fields of human disease treatment or health care.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is:

[0007] The first aspect of the present invention provides a Lactobacillus reuteri (Limosilactobacillus reuteri) MacFasB02 strain, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on July 29, 2024, with the deposit number: GDMCC No: 64918; the 16S rDNA sequence of the Lactobacillus reuteri MacFasB02 strain is shown in SEQ ID No: 1.

[0008] The second aspect of the present invention provides the use of the Lactobacillus reuteri MacFasB02 strain described in the first aspect in the preparation of a lipid-lowering product.

[0009] Preferably, the lipid-lowering product is a product that reduces LDL-C and TG levels.

[0010] The present invention has found through research that the Lactobacillus reuteri MacFasB02 strain can reduce blood lipid levels (including reducing serum LDL-C and TG levels), and is expected to be used to improve hyperlipidemia and related diseases induced by it, such as diabetes.

[0011] The third aspect of the present invention provides the use of the Lactobacillus reuteri MacFasB02 strain described in the first aspect in the preparation of a product for inhibiting weight gain.

[0012] Unlike the general practice of reducing weight by changing diet or increasing exercise, the MacFasB02 strain of Lactobacillus reuteri did not reduce the weight of mice, but it was able to delay weight gain and reduce the increase in weight without changing diet or increasing exercise. In the current situation where high-fat diets are prevalent, it has important application value in inhibiting / preventing excessive weight gain and lowering blood lipid levels in a high-fat environment.

[0013] The fourth aspect of the present invention provides the use of the Lactobacillus reuteri MacFasB02 strain described in the first aspect in the preparation of a liver protection product.

[0014] Preferably, the liver protection product is a product that improves liver lesions and fat accumulation caused by a high-fat diet.

[0015] The present invention has found through research that the Lactobacillus reuteri MacFasB02 strain can alleviate liver cell degeneration caused by a high-fat diet, reduce liver cell cavitation, reduce the gaps between liver cells, and alleviate lipid accumulation in the liver, thus having a good liver-protecting effect.

[0016] The fifth aspect of the present invention provides the use of the Lactobacillus reuteri MacFasB02 strain described in the first aspect in the preparation of a product for relieving rheumatoid arthritis inflammation.

[0017] Rheumatoid arthritis (RA) is a chronic systemic disease characterized by synovitis. Excessive proliferation of the synovium and repeated severe inflammation lead to the destruction of articular cartilage and bone, causing joint fibrosis, joint dysfunction, and ultimately disability of patients. The present invention has found through research that the Lactobacillus reuteri MacFasB02 strain can alleviate the symptoms of collagen-induced rheumatoid arthritis, and can reduce the TNF-α and IL-6 content in serum, has a certain therapeutic effect on rheumatoid arthritis, and brings a new and safe treatment plan for rheumatoid arthritis.

[0018] Preferably, the types of products include health products and medicines.

[0019] The sixth aspect of the present invention further provides a probiotic preparation, wherein the probiotic preparation uses the Lactobacillus reuteri MacFasB02 strain described in the first aspect as a main active ingredient.

[0020] Preferably, the probiotic preparation further comprises a pharmaceutically acceptable excipient.

[0021] More preferably, the excipients include diluents, binders, wetting agents, disintegrants, lubricants, glidants, etc. known in the art. Diluents include but are not limited to starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, calcium hydrogen phosphate, etc.; wetting agents include but are not limited to water, ethanol, isopropanol, etc.; binders include but are not limited to starch slurry, dextrin, syrup, honey, glucose solution, acacia glue slurry, gelatin slurry, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, etc.; disintegrants include but are not limited to dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium dodecyl sulfate, etc.; lubricants and glidants include but are not limited to talc, silicon dioxide, polyethylene glycol, etc.

[0022] Preferably, the dosage form of the probiotic preparation includes injection, tablet, powder, granule, capsule, pill, enteric-coated capsule, etc. The use of the preparation includes but is not limited to oral administration.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The present invention discloses a strain of Lactobacillus reuteri MacFasB02 derived from non-human primates, which is isolated from the feces of crab-eating monkeys that tolerate a high-fat diet. The strain has multiple prebiotic effects, including being able to significantly reduce the levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) caused by a high-fat diet, and having a good lipid-lowering effect; having a good liver-protecting effect; and being able to effectively inhibit the weight gain caused by a high-fat diet without changing the amount of food intake; being able to effectively alleviate the inflammation of rheumatoid arthritis and improve motor dysfunction. At the same time, the strain also has extremely strong acid and bile salt resistance, and is suitable for colonization in the gastrointestinal tract of primates. Since primates are highly similar to humans in terms of intestinal morphology, metabolic mechanism, and physiological function, it is shown that the strain has a natural advantage in improving human health, which is conducive to obtaining a practical and effective application effect. Therefore, the Lactobacillus reuteri MacFasB02 strain has important application value in many fields such as lowering blood lipids, controlling weight gain, protecting the liver, alleviating rheumatoid arthritis inflammation and improving motor dysfunction.

[0025] In addition, compared with existing similar products, this strain is the only Lactobacillus reuteri derived from non-human primates and resistant to high-fat environments. It has strong adaptability to the gastrointestinal tract of primates (including humans), has a wide range of indications and significant effects, and has market prospects for development into live biopharmaceuticals (LBP) or probiotics. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The colony morphology of Limosilactobacillus reuteri MacFasB02 strain;

[0027] Figure 2 The Gram staining results of Limosilactobacillus reuteri MacFasB02 strain;

[0028] Figure 3 is the phylogenetic tree of Limosilactobacillus reuteri MacFasB02 strain;

[0029] Figure 4 The blood lipid results of mice fed with high-fat diet and maintenance diet for 10 weeks;

[0030] Figure 5 The blood lipid results of mice after 13 weeks of intervention with Limosilactobacillus reuteri MacFasB02 strain;

[0031] Figure 6 The curve of body weight changes, growth rate and daily food intake of mice during the intervention period of Limosilactobacillus reuteri MacFasB02 strain;

[0032] Figure 7 The results of H&E and Oil Red O staining of the liver of hyperlipidemic mice treated with Limosilactobacillus reuteri MacFasB02 for 13 weeks (bar: 100 μm);

[0033] Figure 8 The swelling and lesions of the rat's feet;

[0034] Fig. 9 is the change of foot volume before and after intervention in rats;

[0035] Fig.10 Gait changes of rats before and after intervention

[0036] Fig.11Changes in the contents of TNF-α and IL-6 in the serum of rats before and after intervention;

[0037] Fig.12 Growth curve of Limosilactobacillus reuteri MacFasB02 strain;

[0038] Fig.13 Acid and bile salt tolerance test of Limosilactobacillus reuteri MacFasB02 strain (left figure shows different bile salt concentration environments, and right figure shows different pH environments). Specific implementation manners

[0039] The following further describes the specific implementation manners of the present invention. It should be noted here that the description of these implementation manners is used to help understand the present invention, but does not constitute a limitation to the present invention. In addition, the technical features involved in the following various implementation manners of the present invention can be combined with each other as long as they do not conflict with each other.

[0040] The experimental methods in the following examples are all conventional methods unless otherwise specified, and the test materials used in the following examples are all commercially available through conventional channels unless otherwise specified.

[0041] Example 1: Isolation and identification of Limosilactobacillus reuteri MacFasB02 strain

[0042] The Limosilactobacillus reuteri (abbreviated as L. reuteri) MacFasB02 strain was isolated from the feces of a cynomolgus monkey tolerant to a high-fat diet. The steps and results of the isolation and identification are as follows:

[0043] Collect fecal samples of cynomolgus monkeys (aged 6 years, experimental animal use license number: SYXK (Guangdong) 2023 - 0187) tolerant to a high-fat diet raised in the Institute of Zoology, Guangdong Academy of Sciences into a 50 mL sterile centrifuge tube. Add sterile PBS (9 mL of sterile PBS per gram of feces) in a laminar flow hood and mix on a vortex mixer. After mixing, let it stand for 10 min, separate the supernatant and dilute it by 10 6 -10 8 times. Then, take 100 μL and spread it on an MRS agar plate, and culture it at 38 °C for 18 - 24 h. Pick single colonies on the plate and inoculate them on an MRS plate by the streak plate method for purification. Observe the purified colonies and select colonies that are milky white, round, with neat edges, smooth appearance, and a white papilla in the middle at the top ( Figure 1), inoculate them in MRS liquid culture medium, and number them. After culturing for 18-24 hours, take a small amount of bacterial liquid for Gram staining, observe the bacterial morphology under an optical microscope, and select the blue-purple short rod-shaped strain ( Figure 2 ) for 16s rDNA sequencing.

[0044] 16s rDNA sequencing was performed using universal primers (27F: AGAGTTTGATCCTGGCTCAG, 1492R: TACGGCTACCTTGTTACGACTT) and completed by Beijing Qingke Biotechnology Co., Ltd. through Sanger sequencing. The 16s rDNA sequence of each strain was BLAST compared in the Genome database of NCBI. The MacFasB02 strain (its sequence is shown in SEQ ID No: 1) had an E value of 0 compared with other L. reuteri strains known to NCBI, and the identities were all greater than 99%. After constructing a phylogenetic tree, it was found that ( Figure 3 ), MacFasB02 strain is indeed a different strain of Lactobacillus reuteri of the same species.

[0045] At present, the L. reuteri MacFasB02 strain has been deposited in the Guangdong Provincial Microbiological Culture Collection Center (GDMCC) on July 29, 2024, with the deposit number GDMCC No: 64918, and the deposit address is No. 100, Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province.

[0046] Limosilactobacillus reuteri MacFasB02 16s rDNA sequence (2541bp, SEQ IDNo: 1):

[0047] CCTTTCGACTTCACCCCAGTCATCTGTCCCGCCTTAGGCGGCTCCCTCCATAAAGGTTAGGCCACCGACTTTGGGCGTTACAAACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCGATTCCGACTTCGTGTAGGCGAGTTGCAGCCTACAGTCCGAACTGAGAACGGCTTTAAGAGATTAGCTTACTCTCGCGAGCTTGCGACTCGTTGTACCGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGATCTGACGTCGTCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCTCACTAGAGTGCCCAACTTAATGCTGGCAACTAGTAACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACGACCATGCACCACCTGTCATTGCGTCCCCGAAGGGAACGCCTTATCTCTAAGGTTAGCGCAAGATGTCAAGACCTGGTAAGGTTCTTCGCGTAGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCTTAATGCGTTAGCTCCGGCACTGAAGGGCGGAAACCCTCCAACACCTAGCACTCATCGTTTACGGCATGGACTACCAGGGTATCTAATCCTGTTCGCTACCCATGCTTTCGAGCCTCAGCGTCAGTTGCAGACCAGACAGCCGCCTTCGCCACTGGTGTTCTTCCATATATCTACGCATTCCACCGCTACACATGGAGTTCCACTGTCCTCTTCTGCACTCAAGTCGCCCGGTTTCCGATGCACTTCTTCGGTTAAGCCGAAGGCTTTCACATCAGACCTAAGCAACCGCCTGCGCTCGCTTTACGCCCAATAAATCCGGATAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGTGACTTTCTGGTTGGATACCGTCACTGCGTGAACAGTTACTCTCACGCACGTTCTTCTCCAACAACAGAGCTTTACGAGCCGAAACCCTTCTTCACTCACGCGGTGTTGCTCCATCAGGCTTGCGCCCATTGTGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTATGGACCGTGTCTCAGTTCCATTGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATCGCCTTGGTAAGCCGTTACCTTACCAACTAGCTAATGCACCGCAGGTCCATCCCAGAGTGATAGCCAAAGCCATCTTTCAAACAAAAGCCATGTGGCTTTTGTTGTTATGCGGTATTAGCATCTGTTTCCAAATGTTATCCCCCGCTCCGGGGCAGGTTACCTACGTGTTACTCACCCGTCCGCCACTCACTGGTGATCCATCGTCAATCAGGTGCAAGCACCATCAATCAGTTGGGCCAGTGCGTACGACTTGCATGTATTAGGCACACCGCCGGCG。

[0048] Example 2 Function and Application of Limosilactobacillus reuteri Strain MacFasB02

[0049] (1) Limosilactobacillus reuteri strain MacFasB02 can reduce serum cholesterol levels

[0050] Twenty-one 7-week-old C57BL / 6J male mice were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. and raised in the SPF barrier facility of the Animal Research Institute of Guangdong Academy of Sciences (Experimental Animal Use License No.: SYXK (Guangdong) 2023-0329). Animal adaptability training was carried out one week before the start of the experiment, and the mice were guaranteed to eat freely throughout the whole process. Then 3 mice were randomly selected to be fed with conventional maintenance feed (purchased from Guangdong Medical Experimental Animal Center, the formula is shown in Table 1), and the remaining 18 mice were fed with high-fat feed (purchased from Ke'ao Xieli (Tianjin) Feed Co., Ltd., the formula is shown in Table 2) to induce hyperlipidemia mice. When the animals were raised for 10 weeks, 3 mice induced by high-fat feed and mice fed with maintenance feed were randomly selected, and the mouse serum was separated after orbital blood sampling. Guangdong Lane Pharmaceutical Research Institute Co., Ltd. was commissioned to detect TC, TG, LDL-C, and HDL-C indicators. The results showed that after 10 weeks of feeding, the serum TC and LDL-C levels of mice induced by high-fat feed were significantly higher than those of mice fed with maintenance feed (P<0.05, Figure 4 ), indicating that the hyperlipidemia mouse model was successfully established.

[0051] After the model was successfully established, compound antibiotics (ampicillin 1g / L, gentamicin 500mg / L, neomycin 1g / L, penicillin 100U / L) were added to the drinking water of all mice, and vancomycin (1mg / mL) and metronidazole (0.5mg / mL) were given by oral gavage alternately every other day. The antibiotic treatment lasted for 1 week. After that, the water containing compound antibiotics was replaced with normal drinking water, and the remaining 15 mice were divided into two groups, including 8 mice in the high-fat diet + PBS group (referred to as HLP+PBS) and 7 mice in the high-fat diet + L.reuteriMacFasB02 group (referred to as HLP+Lr). The mice were gavaged once a day for 13 consecutive weeks and continued to be fed with high-fat feed. Among them, the HLP+PBS group was gavaged with sterile PBS, and the HLP+Lr group was gavaged with 1×10 10 CFU / mL L.reuteri MacFasB02 in PBS solution. After 13 weeks of intragastric administration, the serum of all mice was separated by orbital blood sampling to detect TC, TG, LDL-C, and HDL-C indicators. The above results show that feeding L.reuteri MacFasB02 can significantly reduce the levels of LDL-C and TG in the serum of mice fed a high-fat diet (P<0.05, Figure 5 ), and has a tendency to reduce TC, and is expected to be used in the preparation of probiotic preparations for lowering blood lipids.

[0052] Table 1 Maintaining feed composition indicators (GB 14924.3-2010)

[0053]

[0054] Table 2 High-fat feed ratio (100 kg per portion)

[0055]

[0056] (2) Limosilactobacillus reuteri MacFasB02 strain can inhibit weight gain in mice

[0057] During the intervention period of L. reuteri MacFasB02 in part (1), the body weight of mice and the high-fat diet intake of mice in each cage were measured weekly (once a week). The results showed that there was no significant difference in the average daily food intake of mice in the HLP+PBS and HLP+Lr groups, and there was no significant difference in the body weight of mice in the same group during the intervention period. However, there was a significant difference in the increase in body weight between the two groups before and after the intervention (P<0.05, Figure 6 ). The above results show that: under the same food intake, L. reuteri MacFasB02 strain can inhibit the weight gain of mice by regulating the metabolism in the mice and reduce the increase in the weight of mice.

[0058] (3) Limosilactobacillus reuteri MacFasB02 has liver protection effect

[0059] In the experiment using L. reuteri MacFasB02 strain for intervention in part (1), the livers of mice gavaged for 13 weeks were collected from the HLP+PBS and HLP+Lr groups, fixed with 4% paraformaldehyde, and commissioned to Wuhan Sevier Biotechnology Co., Ltd. for frozen sectioning, H&E, and Oil Red O staining. The staining results showed that the L. reuteri MacFasB02 strain could significantly improve the liver lesions and fat accumulation caused by a high-fat diet in mice. Among them, the H&E staining results showed that the L. reuteri MacFasB02 strain could alleviate the degeneration of mouse liver cells, reduce hepatocyte cavitation, and reduce the gaps between liver cells. The Oil Red O staining results showed that the L. reuteri MacFasB02 strain could alleviate the lipid accumulation in the liver ( Figure 7 ).

[0060] (4) Lactobacillus reuteri MacFasB02 can relieve rheumatoid arthritis inflammation. Six 7-week-old SD male rats were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. and divided into a normal group (Nomal group) and a treatment group (Treatment group). All experimental animals were adapted to feeding for one week before the experiment began, and free diet was guaranteed throughout the feeding process. Then the Treatment group was modeled for 2 weeks, the antibiotic treatment time was 1 week, and the intervention period was 10 weeks.

[0061] At the beginning of the experiment, the primary immunization was performed. Bovine type II collagen and complete Freund's adjuvant were mixed in equal amounts and emulsified using a vortexer. The emulsification process was kept at a low temperature to prepare a type II collagen emulsion. The emulsion was injected intradermally at the base of the rat's tail at multiple points (0.2 mL / rat). One week after the primary immunization, a booster immunization was performed. The type II collagen emulsion was prepared using the same method and then injected intradermally at the base of the rat's tail (0.1 mL / rat).

[0062] After the model was successfully established, antibiotics (ampicillin 1 g / L, gentamicin 500 mg / L, neomycin 1 g / L, penicillin 100 U / L) were added to the drinking water of all rats, and vancomycin (1 mg / mL) and metronidazole (0.5 mg / mL) were given by oral gavage alternately every other day for 1 week. After that, the water containing antibiotics was replaced with normal drinking water, and the rats in the Treatment group were fed with 1×10 10 Rats in the normal group were gavaged with PBS solution containing CFU / mL L. reuteri MacFasB02, while rats in the normal group were gavaged with sterile PBS at a volume of 0.5 mL / rat / day for 10 weeks.

[0063] After 10 weeks of intervention, the swelling of the ankle joints of the rats in the Treatment group was alleviated, and the degree of finger joint lesions was reduced ( Figure 8 In addition, the volume of the left and right feet of rats in the Treatment group was significantly reduced ( Fig. 9 ), the motor function in the whole walking cycle was significantly improved, and the gait basically returned to normal ( Fig.10 , the red dotted box indicates the gait of the left hind limb of rats in the normal period, RA period and after intervention). The levels of TNF-α and IL-6 in serum were significantly reduced ( Fig.11 The above experimental results show that the strain of Lactobacillus reuteri MacFasB02 has the effect of alleviating the inflammation of rheumatoid arthritis.

[0064] Example 3 Acid and bile resistance of Lactobacillus reuteri MacFasB02 strain

[0065] According to the volume ratio of 1%, 1×10 8 After L. reuteri MacFasB02 was inoculated into MRS medium, the OD of the medium was measured every 2 h for 24 h. 600 The results showed that L. reuteri MacFasB02 reached a stable growth period at 6-8h, and the suspended bacterial density reached the highest value; L. reuteri MacFasB02 produced acid during the growth process, which caused the pH value of the MRS medium to drop to about 4.3 at 6-8h, which was consistent with the time when the growth curve reached a stable growth period ( Fig.12 ); In addition, the survival rate of L. reuteri MacFasB02 was 72.5±7.86% in the environment of pH=3.0, and the survival rate was 148.09±19.13% in the environment of bile salt concentration of 0.5% ( Fig.13 ), which is extremely resistant to acid and bile, and has the potential to colonize in the human intestine.

[0066] In summary, the Lactobacillus reuteri MacFasB02 strain newly isolated from primates for the first time in the present invention has multiple functions, including lowering blood lipid levels (LDL-C and TG), inhibiting weight gain, protecting the liver and relieving rheumatoid arthritis inflammation, and improving motor dysfunction, indicating that the strain has important application prospects in the fields of disease treatment or health care, and is expected to be made into a living biological drug (LPB) or a probiotic preparation to exert its effect.

[0067] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.

Claims

1. A strain of Lactobacillus reuteri MacFasB02, characterized in that: The Lactobacillus reuteri MacFasB02 strain was deposited in the Guangdong Provincial Microbiological Culture Collection Center on July 29, 2024, with the deposit number: GDMCC No: 64918; the 16S rDNA sequence of the Lactobacillus reuteri MacFasB02 strain is shown in SEQ ID No:

1.

2. Use of the Lactobacillus reuteri MacFasB02 strain according to claim 1 in preparing a lipid-lowering product.

3. Use of the Lactobacillus reuteri MacFasB02 strain according to claim 1 in preparing a product for inhibiting weight gain.

4. Use of the Lactobacillus reuteri MacFasB02 strain according to claim 1 in preparing a liver protection product.

5. Use of the Lactobacillus reuteri MacFasB02 strain according to claim 1 in preparing a product for relieving inflammation of rheumatoid arthritis.

6. The use according to claim 2, characterized in that: The lipid-lowering product is a product that reduces low-density lipoprotein cholesterol and triglyceride levels.

7. The use according to claim 4, characterized in that: The liver protection product is a product that improves liver lesions and fat accumulation caused by a high-fat diet.

8. The use according to any one of claims 2 to 7, characterized in that: The types of products described include health products and medicines.

9. A probiotic preparation, characterized in that: The probiotic preparation uses the Lactobacillus reuteri MacFasB02 strain described in claim 1 as a main active ingredient.

10. A probiotic preparation according to claim 9, characterized in that: The probiotic preparation also includes pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Lactobacillus reuteri and application thereof

    CN105062933A

  • Application of breast milk-derived lactobacillus reuteri in reducing fat and regulating fat metabolism rhythm

    CN110205261A

  • Lactobacillus reuteri composition capable of relieving rheumatoid arthritis

    CN110613738A

  • Lactobacillus reuteri with weight reducing function and application of lactobacillus reuteri

    CN111254090A

  • Application of lactobacillus reuteri in preparation of probiotic agent with metabolic regulation effect

    CN116508993A